Jump to content

Ruth Andrew

From Wikipedia, the free encyclopedia

Ruth Andrew
Academic background
EducationUniversity of Strathclyde (PhD, BSc)
Barrhead High School
Academic work
DisciplinePharmacist
Sub-discipline
Steroid biochemistry and applied mass spectrometry
InstitutionsUniversity of Edinburgh

Ruth Andrew is a Scottish academic pharmacist and scientist. She is currently the personal chair of pharmaceutical endocrinology at the University of Edinburgh, and she was awarded a Fellowship of the Royal Society of Edinburgh in 2026.

Early life and education

[edit]

Andrew attended Barrhead High School. In 1985, she studied pharmacy at the University of Strathclyde, and graduated with a Bachelor of Science in 1989.[1] Upon graduation, Andrew attend the Royal Pharmaceutical Society of Great Britain and qualified to practice as a pharmacist.[2]

In 1990, Andrew went back to the University of Strathclyde and studied pharmaceutical chemistry. In 1994, she obtained a Doctor of Philosophy.[1][2]

Career

[edit]

In 1994, Andrew became a lecturer at the University of Edinburgh.[1] In 1995, she joined the Society for Endocrinology.[3]

From June 2012 to August 2016, Andrew was an external examiner for the University of Bradford.[4] In 2015, she was appointed personal chair of pharmaceutical endocrinology at the University.[1]

In 2021, Andrew was elected as the general secretary of the Society for Endocrinology.[5] In 2024, she was appointed the editor-in-chief for the Journal of Endocrinology and the Journal of Molecular Endocrinology.[3] In 2026, Andrew was elected a Fellow of the Royal Society of Edinburgh, in the discipline of biomedical and cognitive sciences.[6]

Research

[edit]

Andrew's research focus is on steroid hormone action in metabolic disease, and mass spectrometry innovations to understand steroid biochemistry and lipid biology.[5]

In April 2019, Andrew was a senior author of a study that looked into 55,000 men who were given 5α-Reductase inhibitors for prostate treatment.[7] Over an 11 year period, the study found out that there was an increase risk of developing type 2 diabetes when taking those inhibitors for treatment.[8][9]

To date, Andrew has authored or co-authored over 200 publications.[4]

Selected publications

[edit]

References

[edit]
  1. 1 2 3 4 "Ruth Andrew". University of Edinburgh. 19 June 2024. Archived from the original on 13 August 2026. Retrieved 13 October 2026.
  2. 1 2 "Ruth Andrew". ResearchGate. Retrieved 13 October 2026.
  3. 1 2 Jonas, Kim, ed. (2023). "Ruth Andrew on meeting your funding needs" (PDF). The Endocrinologist. No. 150. pp. 20–21. ISSN 0965-1128. Retrieved 13 October 2026.
  4. 1 2 "Ruth Andrew". University of Edinburgh. Retrieved 13 October 2026.
  5. 1 2 Simpson, Helen, ed. (2021). "Ruth Andrew, your new General Secretary" (PDF). The Endocrinologist. No. 142. p. 24. ISSN 0965-1128. Retrieved 13 October 2026.
  6. ↑ "Professor Ruth Andrew". Royal Society of Edinburgh. Retrieved 13 October 2026.
  7. ↑ "Prostate medicines linked to type 2 diabetes risk, study suggests". University College London. Retrieved 13 October 2026.
  8. ↑ Wei, Li; Lai, Edward Chia-Cheng; Kao-Yang, Yea-Huei; Walker, Brian R; MacDonald, Thomas M; Andrew, Ruth (10 April 2019). "Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study". The BMJ: l1204. doi:10.1136/bmj.l1204. ISSN 0959-8138. PMC 6456811. PMID 30971393.{{cite journal}}: CS1 maint: article number as page number (link)
  9. ↑ Vundla, Arthur (12 April 2019). "Diabetes link to prostate medicines". Daily Record. Factiva DRECRD0020190412ef4c0002q.